1-4 of 4
Thomas Ervin, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Richard R. Furman, MD, Jeff P. Sharman, MD, Steven E. Coutre, MD, Bruce D. Cheson, MD, John M. Pagel, MD, PhD, Peter Hillmen, MBChB, PhD, Jacqueline C. Barrientos, MD, Andrew D. Zelenetz, MD, PhD, Thomas J. Kipps, MD, PhD, Ian Flinn, MD, PhD, Paolo Ghia, MD, PhD, Herbert Eradat, MD, Thomas Ervin, MD, Nicole Lamanna, MD, Michael Hallek, MD, Bertrand Coiffier, MD, PhD, Andrew R. Pettitt, PhD, FRCPath, Shuo Ma, MD, PhD, Stephan Stilgenbauer, MD, Paula Cramer, MD, Maria Aiello, Dave M. Johnson, Langdon L. Miller, MD, Daniel Li, PhD, Thomas M. Jahn, MD, PhD, Roger D. Dansey, MD, Susan M. O'Brien, MD
Journal: Blood
Blood (2013) 122 (21): LBA-6.
https://doi.org/10.1182/blood.V122.21.LBA-6.LBA-6
Published: 2013
Journal Articles

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Michael Mauro, MD, Jerald Radich, MD, Jorge E. Cortes, MD, Shaker Dakhil, MD, Christopher Keir, MD, Sandy Yi, Martha Wadleigh, MD, Vivian G. Oehler, MD, Thomas Ervin, MD, Stuart Goldberg, MD, Michael Savona, MD, FACP
Journal: Blood
Blood (2013) 122 (21): 4015.
https://doi.org/10.1182/blood.V122.21.4015.4015
Published: 2013
Journal Articles

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Karen Yee, MD, Patricia Kropf, MD, Casey O'Connell, MD, Wendy Stock, MD, Raoul Tibes, MD, PhD, David Rizzieri, MD, Katherine Walsh, MD, Elizabeth A. Griffiths, MD, Gail J. Roboz, MD, Michael Savona, MD, Thomas Ervin, MD, Nikolai A. Podoltsev, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Joseph M. Brandwein, MD, Olatoyosi Odenike, MBBS, Eric J. Feldman, MD, Woonbok Chung, PhD, Sue Naim, Gavin Choy, PharmD, Pietro Taverna, PhD, Yong Hao, PhD, George Dimitrov, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 497.
https://doi.org/10.1182/blood.V122.21.497.497
Published: 2013
Journal Articles

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

James R. Berenson, MD, Thomas Ervin, MD, Ralph V. Boccia, MD, Olcay Batuman, MD, Regina Swift, RN, Christina DiLauro Abaya, BA, Andrew P. Mazar, PhD, Gilad S. Gordon, MD, Steven D. Reich, MD, Jennifer A. Callahan, BA
Journal: Blood
Blood (2008) 112 (11): 5185.
https://doi.org/10.1182/blood.V112.11.5185.5185
Published: 2008